SCHEMBL23833441

SCHEMBL23833441

COc1ncc(NC(=O)c2ccn(Cc3ccccc3)n2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 3/20 0.47
MAPK1 P28482 2/20 0.47
IDH1 O75874 7/20 0.43
ALPL P05186 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TNF P01375 1/20 0.41
NOD2 Q9HC29 1/20 0.41
NOD1 Q9Y239 1/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
APOBEC3G Q9HC16 1/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
AVPR2 P30518 1/20 0.41
GPR27 Q9NS67 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151089 1.00 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1LMNAMAPK1IDH1
SCHEMBL23840305 0.86 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1LMNAMAPK1IDH1
SCHEMBL30150996 0.80 IDH1 (0.45) ALDH1A1LMNAIDH1MAPTMEN1
SCHEMBL23833457 0.80 IDH1 (0.45) ALDH1A1LMNAIDH1MAPTMEN1
SCHEMBL23840609 0.80 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1IDH1TNFNOD2
SCHEMBL25486202 0.78 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1LMNAMAPK1NPC1
SCHEMBL30151063 0.78 GPR27 (0.48) SMN1; SMN2ALDH1A1LMNAMAPK1IDH1
SCHEMBL23833480 0.78 GPR27 (0.48) SMN1; SMN2ALDH1A1LMNAMAPK1IDH1
SCHEMBL23840352 0.77 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1LMNAMAPK1IDH1
SCHEMBL23833399 0.76 MAPT (0.46) ALDH1A1LMNAIDH1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D SMN1; SMN2 428/4885ALDH1A1 2592/4885LMNA 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.